[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: https://doi.org/10.14456/mujps.2015.22Pharm Sci Asia 2015; 42(4), 178-185
 

Prevalence and related factors for injectable vancomycin or teicoplanin-associated thrombocytopenia in a Vietnamese hospital

HT. Nguyen1, T. Pham2, HT. Bui*

1 Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
2 Department of Pharmacy, Thong Nhat Hospital, Ho Chi Minh City, Vietnam


Thrombocytopenia is a rare but dangerous adverse event when using vancomycin and teicoplanin. The objectives of this study were to evaluate the prevalence and related factors for vancomycin or teicoplanin injection associated thrombocytopenia. We conducted a cross-sectional study based on medical records of all patients aged 18 years and over, who were treated for at least 48 hours with vancomycin or teicoplanin injection at Thong Nhat hospital. Patients using oral vancomycin, or who had blood system disorders or platelet reduction associated with an original disease were excluded from this study. Thrombocytopenia was defined as a decrease in platelet count at least 25% from baseline and lower than 100 x 109/L. Thrombocytopenia was observed in 16.2% of patients received vancomycin and 21.9% of patients received teicoplanin (p = 0.292). For vancomycin-associated thrombocytopenia, related factor was sex (male) (OR 5.740; 95% CI 1.155-29.547; p = 0.037) and the appropriateness of drug dosing was a protective factor (OR 0.140; 95% CI 0.031-0.628; p = 0.010). For teicoplanin-associated thrombocytopenia, related factor was treatment in the ICU (OR 5.054; 95% CI 1.077-23.791; p = 0.040) and protective factor was baseline platelet count (? 142 x 109/L) (OR 0.267; 95% CI 0.087-0.823; p = 0.021). Patients treated with injectable vancomycin or teicoplanin should be monitored the number of platelets before and during treatment to minimize the consequences of thrombocytopenia. Dose adjustment should be considered in patients received vancomycin, especially in male. Teicoplanin should be more carefully indicated in patients in ICU department with a low platelet count.


Keyword:

vancomycin injection, teicoplanin injection, thrombocytopenia




Download full paper (PDF File size: 388.24 KB.)





Vol.42
No.4
October - December 2015

See other volume

 


Vol.42
No.3
July - September 2015

See other volume

 


Vol.42
No.2
April - June 2015

See other volume

 


Vol.42
No.1
January - March 2015

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register



    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND